// App-Quantinova.ai

5020 : Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Researchers

Presenter

  • Eric Jay Small

Principal Investigators

  • Jack Youngren

  • George Thomas

  • Charles J. Ryan

  • Robert Evan Reiter

  • Kim N. Chi

  • Primo Lara

  • Tomasz M. Beer

  • Adam Foye

  • Joshi J. Alumkal

  • Matthew Rettig

  • Martin Edwin Gleave

  • Christopher P. Evans

  • Josh Stuart

Medical Centers

  • University of California, Davis Medical Center, Sacramento, CA

  • Oregon Health and Science University, Portland, OR

  • BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, CanadaUniversity of California, Davis, Sacramento, CAUniversity of California, Santa Cruz, Santa Cruz, CA

  • University of California, San Francisco, San Francisco, CA

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • University of California, San Francisco, San Francisco, CA

  • University of California, Los Angeles, Los Angeles, CA

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Androgen receptor

  • Phosphatase and tensin homolog

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Androgen Tear

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved